Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

115
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
115
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

124
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
124
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

92
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
92
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

133
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
133
Role Of Notch Signalling In Intestinal Stem Cell Renewal01:12

Role Of Notch Signalling In Intestinal Stem Cell Renewal

2.0K
Notch signaling was first discovered in Drosophila melanogaster, where it is involved in cell lineage differentiation. Notch signaling regulates the maintenance and differentiation of intestinal stem cells or ISCs by controlling the expression of atonal homolog 1 or Atoh1. Atoh1 directs cells to differentiate into secretory cells.
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
2.0K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

126
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
126

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Decoding MS<sup>n</sup> fragmentation rules of isoquinoline alkaloids: a comprehensive atlas.

Talanta·2026
Same author

Ellagic acid alleviates ulcerative colitis in a GPR35-dependent manner associated with SDH restoration.

Phytomedicine : international journal of phytotherapy and phytopharmacology·2026
Same author

Comprehensive Analysis of Corydalis decumbens From Different Regions Using UHPLC-HRMS and Chemometrics.

Journal of separation science·2025
Same author

In-depth characterization of quinolizidine alkaloids via highly efficient enrichment and multi-stage mass spectrometry.

Talanta·2025
Same author

HSQCid: A Powerful Tool for Paving the Way to High-Throughput Structural Dereplication of Natural Products Based on Fast NMR Experiments.

Analytical chemistry·2025
Same author

An algorithm-driven intelligent mining and identification strategy for natural product mass spectrometry.

Journal of chromatography. A·2024

Related Experiment Video

Updated: May 22, 2025

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
08:53

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Published on: July 27, 2022

799

Bakuchiol mitigates colitis through GPR120 activation.

Fangfang Xu1, Jixia Wang2, Tianyu Zhang3

  • 1Jiangxi Provincial Key Laboratory for Pharmacodynamic Material Basis of Traditional Chinese Medicine, Ganjiang Chinese Medicine Innovation Center, Nanchang 330000, China.

Phytomedicine : International Journal of Phytotherapy and Phytopharmacology
|March 14, 2025
PubMed
Summary

Sishen Wan contains bakuchiol, which effectively treats inflammatory bowel disease (IBD) by activating the GPR120 receptor. This study identifies bakuchiol as a promising novel therapeutic agent for IBD.

Keywords:
BakuchiolGPR120Inflammatory bowel diseaseSishen Wan

More Related Videos

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer
06:24

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

Published on: October 13, 2023

784
DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat
09:04

DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat

Published on: February 27, 2014

47.2K

Related Experiment Videos

Last Updated: May 22, 2025

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
08:53

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Published on: July 27, 2022

799
Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer
06:24

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer

Published on: October 13, 2023

784
DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat
09:04

DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat

Published on: February 27, 2014

47.2K

Area of Science:

  • Pharmacology
  • Gastroenterology
  • Traditional Chinese Medicine

Background:

  • Sishen Wan (SSW) is a traditional Chinese herbal formula used for inflammatory bowel disease (IBD).
  • The specific active compounds and mechanisms of SSW in treating IBD remain largely unknown.
  • This study aimed to elucidate the key components and action mechanisms of SSW.

Purpose of the Study:

  • Identify the primary active compound in Sishen Wan (SSW).
  • Evaluate the therapeutic efficacy of the identified compound in an inflammatory bowel disease (IBD) model.
  • Explore the molecular targets and mechanisms underlying its anti-inflammatory effects.

Main Methods:

  • Ultra-high-performance liquid chromatography coupled with mass spectrometry (UHPLC-MS/MS) for chemical analysis.
  • Dextran sodium sulfate (DSS)-induced colitis mouse model to assess therapeutic effects.
  • Virtual screening, pharmacological assays, RNA sequencing (RNA-seq), and cell-based assays to determine molecular targets and mechanisms.

Main Results:

  • Bakuchiol was identified as the main active component of SSW.
  • Bakuchiol demonstrated significant therapeutic effects in DSS-induced colitis, comparable or superior to mesalazine.
  • Bakuchiol acts as a GPR120 agonist, suppressing inflammatory pathways and partially maintaining epithelial barrier function.

Conclusions:

  • Bakuchiol is a key active compound in Sishen Wan (SSW).
  • Bakuchiol exerts therapeutic effects in IBD by activating the GPR120 receptor.
  • Bakuchiol shows potential as a novel therapeutic agent for inflammatory bowel disease (IBD).